Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Clinical effects of assessing electronic patient-reported outcomes monitoring symptomatic toxicities during breast cancer therapy: a nationwide and population-based study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Electrochemotherapy for Breast Cancer-Results From the INSPECT Database

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk of skin cancer following tamoxifen treatment in more than 16,000 breast cancer patients: a cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Diagnostic radiological examinations and risk of intracranial tumours in adults-findings from the Interphone Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pooled analysis of recent studies of magnetic fields and childhood leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Postoperative epilepsy and survival in glioma patients: a nationwide population-based cohort study from 2009 to 2018

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The involvement of cancer patients in symptom reporting talks into our cultural narrative of empowerment and participation in decisions in health of both patients and professionals. Electronic patient-reported outcome (ePRO) is a tool applied for use in such interaction. Based on limited evidence and few empirical studies, health systems are rapidly implementing this instrument in managing patients in active treatment and in follow-up. In a cluster randomized trial of all Danish oncology departments treating breast cancer with adjuvant chemotherapy, we applied ePRO in 347 patients consecutively recruited. Our primary outcome, which was at least one treatment adjustment, was not significantly influenced using ePRO, 34% in the ePRO arm and 41% in the usual care arm received at least one treatment adjustment, p = 0.095. Number of hospitalizations and events of febrile neutropenia were not influenced by the intervention. We believe that one of the main reasons for this finding could be the application of PRO in a well-regulated treatment setting within a public health care system where the most impacting symptomatic toxicities are already taken care off.Trial registration: Clinicaltrials.gov identifier: NCT02996201, registered 19 Dec 2016, retrospectively registered.

Original languageEnglish
JournalBreast Cancer: Basic and Clinical Research
Volume28
Issue number5
Pages (from-to)1096-1099
Number of pages4
ISSN1178-2234
DOIs
Publication statusPublished - Sep 2021

Bibliographical note

© 2021. The Japanese Breast Cancer Society.

ID: 70124502